Why haven't GLP-1s exploded in India yet?
This is surprising, but I think it is still early days for mass adoption of GLP-1s in India.
Back in December, when I spoke to people in the industry, the expectation was simple: generics would launch in March at around Rs 2,000 and the category would boom.
Clearly, the market is moving slower than many expected.
At the same time, the ground reality is shifting.
When I checked with people in South Delhi and Mumbai in January, the response was mostly: no one has really considered Mounjaro.
Now the response feels different: everyone who can afford it is trying it, asking about it, or knows someone who is on it.
I would still bet that within the next 12 months, every serious pharmacist, doctor network, obesity clinic, premium wellness centre, and eventually even broader healthcare player will have some GLP-1 pathway.
Why the category may still be early, not weak.
The drivers are too strong to ignore.
- Consumers will see other people getting thinner with what looks like relatively low effort.
- Better solutions will emerge for jabbing at home.
- More doctors will get comfortable prescribing them.
- The stigma around GLP-1s will start to fade.
So this may begin as a rich-person weight-loss category. But it probably does not end there.
Markets like this often move through visible behavior before they move through formal advertising.
Someone loses weight. Someone else asks. Someone else tries. Then a doctor, pharmacist, or wellness clinic becomes the access point.
And suddenly what felt like a controversial medical intervention starts to look more like a consumer behavior shift.
From product adoption to culture shift.
With health becoming such a central topic for Indians, I think our worldview may slowly shift from indulgence as status to discipline as status.
From khaate-peete ghar se hai to health ka khayal rakhta hai.
That is what makes this category interesting. The real story may not be pharma adoption alone. It may be the product-to-consumption-to-culture cycle playing out in public.
The key question is not whether GLP-1s are visible already. They are. The real question is how long it takes before the surrounding access points and social normalization catch up enough for the category to feel inevitable.